Cited by 7Systemic Lupus Erythematosus ResearchBlood Coagulation and Thrombosis MechanismsReproductive System and Pregnancy

Identifying Additional Risk Factors for Thrombosis and Pregnancy Morbidities Among Antiphospholipid Antibodies Carriers

Open access
Zuo, Yu, Fan, Jennifer, Sarode, Ravi, Zhang, Song, Makris, Una E., Karp, David R., Shen, Yu-Min·2018·Clinical and Applied Thrombosis/Hemostasis

Abstract

The evaluation of thrombotic and pregnancy risks associated with antiphospholipid antibodies (aPL)in individual patients without antiphospholipid syndrome (APS) clinical manifestation is challenging. Our aim is to identify additional risk factors or potential candidate “second hits” for APS clinical events in a large cohort of ethnically diverse aPL-positive patients. We included 219 consecutive aPL-positive patients who attended clinic at our institution. All patients had at least 1 persistent high titer (≥99 percentiles) aPL. Independent risk factors for thrombosis and pregnancy morbidities among patients with positive aPL were evaluated. When assessing risk factors associated with pregnancy morbidities, only female controls of reproductive age (age ≤45) were used. Pearson χ 2 analysis and multivariable logistic regression were used to evaluate correlation between different risk factors and clinical manifestations. Of the 219 aPL-positive patients, 120 (54.8%) patients had criteria APS clinical manifestations and 99 patients did not. A total of 46.1% were Caucasian, 26.4% of African descent, 16.9% Hispanic, 1.8% Asian, and 8.7% were unspecified. Among traditional risk factors and signs of endothelial injury, only hypertension demonstrated an independent association with arterial thrombosis (odds ratio [OR] = 3.826, 95% confidence interval [CI]: 1.597-9.167, P = .0026), and lupus anticoagulant (LA) demonstrated an independent association with venous thrombosis (OR = 3.308, 95% CI: 1.544-7.085, P = .0021). None of the evaluated risk factors demonstrated a significant association with pregnancy morbidity. Hypertension is a potential predictor of arterial thrombosis and the presence of LA is a potential predictor of venous thrombosis in aPL-positive patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/1076029618755946

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In patients with systemic lupus erythematosus, long-term exposure to hydroxychloroquine is associated with a reduction in both first and recurrent thrombotic events, particularly in those with persistent antiphospholipid antibody positivity.

    “In patients with SLE, long-term exposure to HCQ has consistently been associated with a reduction in both first and recurrent thrombotic events, particularly in those with persistent aPL positivity [6, 7].”

    From Hydroxychloroquine as an Adjunct Therapy for Secondary Thrombosis Prevention in Primary Antiphospholipid Syndrome: A Systematic Review and Meta-analysis (2026) · cites this paper as [7]

    The Results and Discussion report thrombotic risk factors among persistently aPL-positive patients, but do not address whether hydroxychloroquine reduces first or recurrent events in patients with SLE. Searches for “hydroxychloroquine,” “HCQ,” and recurrent thrombosis with protective treatment found no passage assessing that association. The cited copy does not verify the claim. (LLM, conf=0.76)

    Experimental — accuracy not yet measured
  • In systemic lupus erythematosus, multiple observational studies have consistently shown that long-term antimalarial use reduces both first and recurrent thrombotic events, particularly among those with persistent antiphospholipid antibodies.

    “Multiple observational studies have consistently shown that long-term antimalarial use reduces both first and recurrent thrombotic events in patients with SLE, particularly among those with persistent antiphospholipid antibodies [6, 7].”

    From Hydroxychloroquine as an Adjunct Therapy for Secondary Thrombosis Prevention in Primary Antiphospholipid Syndrome: A Systematic Review and Meta-analysis (2026) · cites this paper as [7]

    The Results and Discussion (page unavailable) examine thrombotic risk factors in people with persistent antiphospholipid antibodies, but do not report whether antimalarial use reduces thrombosis in SLE. Searches for antimalarial, hydroxychloroquine, and chloroquine found no passage addressing long-term use or prevention of first and recurrent events. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 31 · Cited by 7

Authors
Zuo, Y., Fan, J., Sarode, R., Zhang, S., Makris, U. E., Karp, D. R., & Shen, Y.-M.
Affiliations
  • The University of Texas Southwestern Medical Center (US)
  • VA North Texas Health Care System (US)
Corresponding author
Shen, Yu-Min
Venue
Clinical and Applied Thrombosis/Hemostasis
Published
2018-02-22
Volume
24
Issue
6
Pages
980-985
ISSN
  • 1076-0296 (ISSN-L)
  • 1938-2723
OpenAlex
W2789080862
Cited by
7
References
31
Citations by year
2026: 1 · 2024: 1 · 2023: 1 · 2021: 1 · 2019: 1 · 2018: 2
FWCI
0.85
Type
journal article
Language
en
Open access
Locations
  • Clinical and Applied Thrombosis/Hemostasis (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
NIH/NCAT (UL1TR001105)
Topics
  • Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
  • Life Sciences › Immunology and Microbiology › Immunology › Reproductive System and Pregnancy
Keywords
antiphospholipid antibodies, antiphospholipid syndrome, thrombosis risk factors, pregnancy morbidity, arterial thrombosis, venous thrombosis, hypertension, lupus anticoagulant, endothelial injury, ethnic diversity
MeSH terms
Adult, Female, Humans, Middle Aged, Pregnancy, Pregnancy Complications, Cardiovascular, Risk Factors, Antibodies, Antiphospholipid, Venous Thrombosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review